NP2 Leadership Team

Forward-Thinking Talent Dedicated to Changing the Face of Pharmaceutical Care in the U.S.

Together we will mitigate the forces that keep drug prices high and help create health equity.

Bill Buhles

Co-Founder + CEO

Bill came out of retirement to co-found NP2 in 2019, fulfilling a long-held dream to establish a nonprofit pharma organization that would bring lifesaving drugs to market while putting patients ahead of profits.

As CEO, Bill oversees the strategic direction of NP2 and he is actively involved in the day-to-day workings of the organization including all aspects of our drug program and operations. Bill also serves as the President of NP2’s Board of Directors.

Bill is a pharmaceutical scientist with a three-decade track record of success as a clinical leader in bringing life-saving medicines to market. He designed and ran Phase I, II, and III clinical trials in virology, oncology, and transplantation and oversaw later stages of drug development including authoring and submitting new drug applications to the FDA and European Union. Bill holds a Ph.D. in Microbiology and Immunology and a Doctor of Veterinary Medicine, both from the University of California, Davis.

Jacob P. Lalezari

Co-Founder + Board Vice President

Jay is the Chief Executive Officer and Director of Quest Clinical Research in San Francisco and has served as a principal investigator for Phase I, II, and III clinical studies of new therapies for viral diseases including HIV/AIDS, CMV, HPV, HSV, Hepatitis B &C, Influenza, RSV and cancer. He has published many research papers and presented research at numerous international conferences. Dr. Lalezari holds an M.A. degree in English Literature from the University of Virginia and earned his M.D. at the University of Pennsylvania.

Terri Miller

Executive Director

Terri joined NP2 as its Executive Director in 2021. In her leadership role, Terri oversees the organization’s day-to-day operations, budgeting, fundraising, marketing, and strategic initiatives.  She is also a non-voting member of the NP2 Board of Directors.

Terri has more than three decades of successful experience in nonprofit management having served as a Director of Development & Communications, Board President, Interim Director, and a results-oriented strategic consultant to dozens of nonprofit organizations working in a variety of mission-based areas.

Terri holds an MPA degree with an emphasis in nonprofit management from San Francisco State University.

Kevin Bittorf

Chief Manufacturing Officer

Kevin began consulting with NP2 in 2020 and has been a valued leadership team member ever since. Kevin became Chief Manufacturing Officer in 2023, and in this capacity, he oversees our drug manufacturing process including identifying strategic partners and collaborators that possess the needed expertise, reputation in quality and reliability, and cost-efficiencies that will allow NP2 to successfully fulfill its mission to bring lifesaving drugs to market at substantially reduced prices.

He is an accomplished senior executive with demonstrated success in pharmaceutical development and manufacturing from feasibility to commercialization.  He has also played a key role in the implementation of innovative technologies and securing licensing deals, resulting in bringing more than 30 products to market.

Kevin holds a Ph.D. in Chemical Engineering and an MBA, both from the University of Alberta. Kevin is also a registered professional engineer.